Sigvotatug vedotin Phase I Data for NSCLC Presented at ASCO 2024

Updated Phase I clinical trial results for Pfizer's Sigvotatug vedotin (SGN-B6A), an investigational antibody-drug conjugate (ADC) targeting integrin beta-6 (IB6), were presented at ASCO 2024. The drug demonstrated promising results in treating non-small cell lung cancer (NSCLC), with an objective response rate (ORR) of 19.0% across all dose groups for NSCLC patients and 31% among those who were taxane-naive.

Sigvotatug vedotin is undergoing extensive investigation to confirm its efficacy and safety. The aim is to significantly improve treatment outcomes for patients with NSCLC. The drug delivers its cytotoxic payload directly to cancer cells by selectively binding to the IB6 protein, found in over 90% of NSCLC tumors, thereby minimizing off-target effects.

The trials included patients who had previously undergone cancer treatment. The drug's safety profile was found to be manageable, and it exhibited promising tumor response and durable responses. Research is ongoing to assess its potential in combination therapies, including with pembrolizumab, which could reshape the lung cancer treatment landscape.

Pfizer has identified oncology as a key strategic area, aiming to develop eight blockbuster cancer drugs by 2030. The company bolstered its position in the ADC space through the acquisition of Seagen, bringing potential drugs like Sigvotatug vedotin into its portfolio. The drug is now being studied in a global Phase III trial (SGNB6A-002; NCT06012435) for second- and third-line treatment in taxane-naive patients, with results anticipated between 2026 and 2027.